Pharma & HealthcareTop Companies
Pharma & Healthcare

Top Blood Bank Market Companies - Rankings, Profiles, Market Share, SWOT & Strategic Outlook

Industry

Pharma & Healthcare

Published

Feb 2026

Share:

Pharma & Healthcare

Top Blood Bank Market Companies - Rankings, Profiles, Market Share, SWOT & Strategic Outlook

$3,590

Choose License Type

Only one user can use this report

Additional users can access this report

You can share within your company

Company Contents

Quick Facts & Snapshot

2025 Market Size (US$)
20.80 Billion
2026 Forecast (US$)
22.20 Billion
2032 Forecast (US$)
33.00 Billion
CAGR (2025-2032)
6.90%

Summary

The Blood Bank market is entering a disciplined growth phase as hospitals demand safer, more efficient collection, testing, and inventory management. Leading Blood Bank market companies consolidate share through automation, integrated IT, and cold-chain strength, while specialized regional players defend niches. With global revenues reaching US$ 20.80 Billion in 2025 and a 6.90% CAGR forecast through 2032, competition is intensifying.

2025 Revenue of Top Blood Bank Suppliers
ReportMines Logo

Source: Secondary Information and ReportMines Research Team - 2026

Ranking Methodology

The ranking of Blood Bank market companies is based on a composite score combining quantitative and qualitative indicators. Quantitative factors include estimated 2025 Blood Bank revenue, multi-year revenue growth, and size of installed base across collection centers, hospital blood banks, and regional networks. Qualitative factors include technology differentiation in screening, automation, and informatics; breadth of product and service portfolio; regulatory compliance track record; and geographic coverage in mature and emerging markets. We also evaluate success in winning long-term supply and maintenance contracts, participation in national transfusion programs, and depth of clinical and technical support. Each company is scored on a standardized 1–10 scale per criterion, weighted toward revenue, installed base, and technology leadership. Final rankings reflect the aggregated weighted score, cross-checked against public disclosures, expert interviews, and procurement benchmarks.

Top 10 Companies in Blood Bank

1
Terumo BCT, Inc.
North America, Europe, Asia Pacific
Expanded cell-processing portfolio, deepened partnerships with large hospital networks, and invested in AI-driven device analytics.
Apheresis systems, blood component separation, cell processing technologies
Lakewood, Colorado, USA
Automated collection platforms and advanced apheresis technologies for high-volume blood centers
US$ 2.10 Billion
2
Fresenius Kabi AG
Europe, North America, Latin America
Strengthened US presence, launched next-generation collection sets, and expanded manufacturing capacity in Asia.
Blood collection systems, leukoreduction, transfusion technologies
Bad Homburg, Germany
End-to-end blood collection solutions with strong disposables and device integration capabilities
US$ 1.85 Billion
3
Haemonetics Corporation
North America, Europe, Asia Pacific
Rolled out cloud-based donor management, acquired niche software assets, and intensified focus on plasma collection customers.
Apheresis, donor management software, blood management analytics
Boston, Massachusetts, USA
Integrated hardware-software ecosystems for donor centers and hospital transfusion services
US$ 1.60 Billion
4
Grifols, S.A.
Europe, North America, Middle East
Enhanced NAT screening offerings and pursued strategic partnerships in the Middle East and Latin America.
Plasma-derived therapies, blood typing, screening reagents, and analyzers
Barcelona, Spain
Reagent and diagnostics-focused portfolio supporting large transfusion networks and plasma centers
US$ 1.40 Billion
5
bioMérieux SA
Europe, North America, Asia Pacific
Launched updated test menus for blood-borne pathogens and invested in automated lab workflow solutions.
Infectious disease screening, microbiology, and blood safety diagnostics
Marcy-l'Étoile, France
High-throughput infectious disease testing platforms for blood screening laboratories
US$ 1.10 Billion
6
Ortho Clinical Diagnostics (QuidelOrtho)
North America, Europe, Middle East & Africa
Integrated product lines post-merger and refreshed automated blood typing solutions for mid-sized hospitals.
Immunohematology, blood typing, and transfusion testing systems
Raritan, New Jersey, USA
Serology and immunohematology analyzers for hospital-based blood banks and reference labs
US$ 0.95 Billion
7
Immucor, Inc.
North America, Europe
Expanded molecular typing portfolio and partnered with regional blood services for advanced reference testing.
Transfusion diagnostics, donor screening, molecular typing
Norcross, Georgia, USA
Specialized immunohematology reagents and automated platforms for complex antibody investigations
US$ 0.70 Billion
8
Cerus Corporation
North America, Europe, select Asia Pacific markets
Secured additional national tenders in Europe and advanced clinical evidence for broader use cases.
Pathogen reduction technologies for platelets and plasma
Concord, California, USA
Interception-based pathogen inactivation systems to improve blood safety
US$ 0.55 Billion
9
Macopharma SA
Europe, Middle East, Africa
Expanded eco-friendly product lines and invested in local manufacturing hubs in the Middle East.
Blood bags, transfusion sets, and disposable components
Tourcoing, France
High-quality blood collection and storage consumables for regional blood services
US$ 0.45 Billion
10
Sichuan Nigale Biomedical Co., Ltd.
China, Southeast Asia
Broadened export footprint in ASEAN and launched upgraded screening kits for tier-2 hospitals.
Blood collection devices, reagents, and basic screening instruments
Chengdu, China
Cost-competitive solutions tailored for emerging-market hospital blood banks
US$ 0.30 Billion

Source: Secondary Information and ReportMines Research Team - 2026

Detailed Company Profiles

1

Terumo BCT, Inc.

Terumo BCT, Inc. is a global leader in blood component technologies, apheresis systems, and cell processing solutions serving high-volume centers.

Key Financials: 2025 Blood Bank revenue US$ 2.10 Billion; estimated segment growth 7.20% CAGR 2025-2032.
Flagship Products: Trima Accel, Spectra Optia, Reveos.
2025-2026 Actions: Scaled automated whole blood processing deployments and expanded digital monitoring tools for large donor networks.
Three-line SWOT: Strong global apheresis installed base; Higher device pricing than regional competitors; Opportunity—automation upgrades in emerging blood services.
Notable Customers: American Red Cross, Japanese Red Cross Society, large European national blood services.
2

Fresenius Kabi AG

Fresenius Kabi AG delivers comprehensive blood collection systems and consumables, supporting hospital banks and national transfusion programs worldwide.

Key Financials: 2025 Blood Bank revenue US$ 1.85 Billion; operating margin 15.30%.
Flagship Products: Compomat G5, Aurora cell separators, Fenwal blood bags.
2025-2026 Actions: Increased automation in collection centers and localized production facilities in Asia for disposables.
Three-line SWOT: Broad portfolio from devices to disposables; Dependence on hospital capital budgets; Opportunity—rising demand for leukoreduced components.
Notable Customers: German Red Cross, major Latin American blood centers, multi-hospital health systems.
3

Haemonetics Corporation

Haemonetics Corporation focuses on integrated apheresis platforms and software that optimize donor management and blood utilization in hospitals.

Key Financials: 2025 Blood Bank revenue US$ 1.60 Billion; R&D intensity 8.80% of sales.
Flagship Products: NexSys PCS, MCS+ Apheresis, SafeTrace Tx.
2025-2026 Actions: Expanded cloud-native donor management solutions and analytics-driven optimization services for plasma and blood collection networks.
Three-line SWOT: Strong integration of software and hardware; Exposure to plasma market volatility; Opportunity—data-driven optimization for large health systems.
Notable Customers: Canadian Blood Services, US hospital networks, leading plasma collection companies.
4

Grifols, S.A.

Grifols, S.A. combines plasma-derived therapies expertise with robust blood testing and screening solutions for transfusion services.

Key Financials: 2025 Blood Bank revenue US$ 1.40 Billion; estimated Blood Bank segment growth 6.50% CAGR.
Flagship Products: Procleix NAT systems, Erytra Eflexis, DG Gel cards.
2025-2026 Actions: Expanded NAT testing collaborations and increased footprint in integrated screening laboratories in Europe and the Middle East.
Three-line SWOT: Recognized brand in plasma and diagnostics; Some product overlap in crowded reagent markets; Opportunity—national screening program upgrades.
Notable Customers: Spanish national blood services, Middle Eastern transfusion centers, large integrated laboratories.
5

bioMérieux SA

bioMérieux SA provides infectious disease diagnostics and automation tools that protect blood supplies from transfusion-transmitted pathogens.

Key Financials: 2025 Blood Bank revenue US$ 1.10 Billion; operating margin 17.40%.
Flagship Products: VIDAS, BACT/ALERT, FilmArray panels for blood screening support.
2025-2026 Actions: Broadened pathogen test menus and optimized workflows for high-throughput screening laboratories.
Three-line SWOT: Deep microbiology expertise; Limited direct presence in blood bag hardware; Opportunity—stricter infection control standards globally.
Notable Customers: European reference labs, North American hospital labs, regional blood centers in Asia Pacific.
6

Ortho Clinical Diagnostics (QuidelOrtho)

Ortho Clinical Diagnostics, now QuidelOrtho, specializes in immunohematology and transfusion testing for hospital and reference blood banks.

Key Financials: 2025 Blood Bank revenue US$ 0.95 Billion; estimated 6.10% annual revenue growth.
Flagship Products: ORTHO VISION Analyzer, Ortho BioVue, Ortho Workstation.
2025-2026 Actions: Rationalized product portfolio after merger and upgraded automation features across blood typing platforms.
Three-line SWOT: Strong brand in immunohematology; Integration complexity post-merger; Opportunity—demand for fully automated serology in mid-tier hospitals.
Notable Customers: US community hospitals, European university hospitals, Middle Eastern referral centers.
7

Immucor, Inc.

Immucor, Inc. is a specialist in transfusion diagnostics and molecular typing solutions for complex immunohematology cases.

Key Financials: 2025 Blood Bank revenue US$ 0.70 Billion; R&D investment 10.20% of revenue.
Flagship Products: Echo Lumena, NEO Iris, PreciseType molecular assays.
2025-2026 Actions: Strengthened molecular product line and expanded collaborations with tertiary care hospitals and national reference labs.
Three-line SWOT: Niche expertise in complex antibody identification; Smaller geographic footprint than mega-players; Opportunity—growth in precision transfusion medicine.
Notable Customers: Specialist reference laboratories, tertiary hospitals, regional blood services in North America and Europe.
8

Cerus Corporation

Cerus Corporation focuses on pathogen reduction technologies that enhance blood safety for platelets and plasma.

Key Financials: 2025 Blood Bank revenue US$ 0.55 Billion; segment growth 9.30% CAGR projected.
Flagship Products: INTERCEPT Blood System for Platelets, INTERCEPT Blood System for Plasma.
2025-2026 Actions: Expanded reimbursement coverage and secured multi-year agreements with national blood operators in Europe.
Three-line SWOT: Unique regulatory-approved pathogen reduction platform; Reliant on policy adoption timelines; Opportunity—regulatory preference for pathogen-reduced components.
Notable Customers: French National Blood Service, selected US and European blood centers, hospital-based transfusion services.
9

Macopharma SA

Macopharma SA manufactures blood bags and consumables supporting safe collection, processing, and storage in regional blood services.

Key Financials: 2025 Blood Bank revenue US$ 0.45 Billion; operating margin 11.80%.
Flagship Products: Triple blood bag systems, platelet storage solutions, leukoreduction filters.
2025-2026 Actions: Expanded sustainable product lines and established new distribution partnerships in Africa and the Middle East.
Three-line SWOT: Strong reputation in consumables quality; Limited automation offerings; Opportunity—growing demand for premium bags in emerging markets.
Notable Customers: European blood centers, Middle Eastern ministries of health, African national blood services.
10

Sichuan Nigale Biomedical Co., Ltd.

Sichuan Nigale Biomedical Co., Ltd. offers cost-effective blood collection and basic screening solutions targeting emerging-market hospital blood banks.

Key Financials: 2025 Blood Bank revenue US$ 0.30 Billion; rapid regional growth 12.50% annually in Asia.
Flagship Products: Blood collection sets, basic immunoassay kits, screening analyzers.
2025-2026 Actions: Scaled exports to Southeast Asia and invested in quality upgrades to meet broader regulatory requirements.
Three-line SWOT: Competitive pricing and local manufacturing; Limited advanced automation portfolio; Opportunity—expansion into underserved secondary hospitals.
Notable Customers: Provincial Chinese hospitals, Southeast Asian hospital chains, regional blood centers.

SWOT Leaders

Terumo BCT, Inc.

SWOT Snapshot

SWOT
Strengths

Dominant apheresis installed base, strong global service network, and broad automation portfolio spanning collection to processing.

Weaknesses

Premium pricing and complex systems can limit adoption among resource-constrained blood centers in low-income markets.

Opportunities

Growing shift toward component therapy, automation in emerging economies, and expansion into cell therapy manufacturing services.

Threats

Intensifying competition from lower-cost Asian device manufacturers and potential reimbursement pressure on donation procedures.

Fresenius Kabi AG

SWOT Snapshot

SWOT
Strengths

Comprehensive devices-and-disposables offering, strong hospital relationships, and diversified presence across therapeutic nutrition and infusion.

Weaknesses

High dependence on mature markets with slower volume growth and exposure to hospital capital expenditure cycles.

Opportunities

Upgrading legacy collection infrastructure, rising leukoreduction adoption, and continued penetration in Latin America and Asia.

Threats

Regulatory price controls, supply-chain disruptions for plastics, and competition from nimble regional consumable suppliers.

Haemonetics Corporation

SWOT Snapshot

SWOT
Strengths

Powerful integration of hardware, software, and analytics with deep expertise in donor management and plasma collection.

Weaknesses

Concentration in North America and reliance on large plasma customers increases exposure to localized shocks.

Opportunities

Globalization of data-driven optimization, cloud migration of donor platforms, and expansion into hospital blood management.

Threats

Cybersecurity risks to cloud solutions, tightening plasma regulations, and rising competition from IT-centric newcomers.

Blood Bank Market Regional Competitive Landscape

North America remains the most mature Blood Bank market, with high automation levels and stringent regulatory standards. Terumo BCT, Inc., Fresenius Kabi AG, and Haemonetics Corporation lead large contracts with organizations such as the American Red Cross and multi-hospital health systems, while Blood Bank market companies focused on software and analytics increasingly shape procurement decisions.

Europe features a consolidated landscape with strong national blood services and coordinated procurement. Grifols, S.A., bioMérieux SA, and Macopharma SA hold significant share in diagnostics and consumables. Blood Bank market companies benefit from harmonized quality standards, but face tight pricing and sustainability requirements driving innovations in eco-friendly collection and cold-chain solutions.

Asia Pacific is the fastest-growing region, driven by expanding hospital infrastructure, rising surgical volumes, and government investments in safety. Terumo BCT, Inc. and Fresenius Kabi AG compete with regional players such as Sichuan Nigale Biomedical Co., Ltd. Blood Bank market companies increasingly localize manufacturing and adapt product portfolios to tier-2 and tier-3 city needs.

Latin America shows mixed maturity, with advanced national blood services in larger economies and infrastructure gaps elsewhere. Fresenius Kabi AG and Grifols, S.A. leverage long-term partnerships with ministries of health, while smaller Blood Bank market companies provide cost-effective consumables. Key drivers include hemovigilance programs and regional standardization of donor management.

The Middle East and Africa region is characterized by uneven access to safe blood and growing modernization initiatives. Macopharma SA and bioMérieux SA expand via partnerships and donor-funded projects, while Cerus Corporation benefits from interest in pathogen reduction. Blood Bank market companies must navigate procurement complexity, donor shortages, and limited local technical capabilities.

Globally, cross-border collaboration and pandemic preparedness strategies are reshaping demand. International NGOs and development agencies increasingly influence tenders in low- and middle-income countries, opening opportunities for both leading Blood Bank market companies and agile regional suppliers that can offer scalable, maintenance-light solutions.

Blood Bank Market Emerging Challengers & Disruptive Start-Ups

Emerging Challengers & Disruptive Start-Ups

HemoCloud Analytics
Disruptor
USA

Cloud-native platform that aggregates blood bank, laboratory, and hospital data to optimize inventory, reduce wastage, and forecast demand using predictive algorithms.

RedTrace Digital
Disruptor
Germany

Blockchain-enabled traceability solution that tracks blood units from donor to recipient, enhancing hemovigilance and regulatory compliance in fragmented healthcare systems.

PlasmoNext Technologies
Disruptor
India

Low-cost, semi-automated apheresis and plasma collection devices designed for high-throughput government centers in resource-constrained regions.

SafeBag BioSolutions
Disruptor
Belgium

Next-generation blood bag materials with extended shelf life, embedded RFID tagging, and reduced plastic content for sustainability-focused blood services.

DonorLink Mobile
Disruptor
Brazil

Mobile-first donor recruitment and engagement platform that integrates appointment scheduling, rewards, and geolocation to increase voluntary donation rates.

PathoShield Labs
Disruptor
South Korea

Compact, rapid multiplex screening cartridges enabling near-patient infectious disease testing for smaller hospital-based blood banks.

Blood Bank Market Future Outlook & Key Success Factors (2026-2032)

From 2025 to 2031, cumulative investments in metro expansions and station safety upgrades are projected to surpass significant amounts. The total market will scale from US$ 2.27 Billionin 2025 to US$ 3.38 Billion by 2031, reflecting a 6.90% CAGR. Winning Blood Bank market companies will share several attributes. First, they will embed native IoT sensors, enabling predictive maintenance contracts that can double recurring revenue within five years. Second, modular design philosophies—interchangeable panels, plug-and-play controllers—will shorten installation windows and appeal to cost-sensitive public operators.

Localization strategies will also define competitive edges. Suppliers that establish regional assembly plants to meet content rules in India, Brazil, or the U.S. are likely to capture bonus points in tenders. Finally, sustainability credentials will move from optional to mandatory. Recyclable composite panels, energy-efficient brushless motors, and life-cycle carbon disclosures will become bid differentiators. In short, the coming decade rewards Blood Bankmarket companies that marry digital intelligence with manufacturing agility and regulatory foresight.

Frequently Asked Questions

Find answers to common questions about this company report.